Meds & supplements › Elacestrant
Medicine · Estrogen Receptor Antagonist
Elacestrant
ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1 -mutated advanced or metastatic breast cancer
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
Drug facts
- Used for
- ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1 -mutated advanced or metastatic breast cancer
What it is used for
ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1 -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Side effects, and when to stop
The following clinically significant adverse reactions are described elsewhere in the labeling:
- Dyslipidemia
Who should not take it
None.
Storing it
Storage and Handling
Store at 20°C to 25°C (68°F to 77°F). Excursions permitted from 15°C to 30°C (59°F to 86°F)..
Cite this page
- NLM
sofidex [Internet]. Daloreum; c2026. Elacestrant; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/elacestrant
- APA 7th
sofidex. (2026, August 2). Elacestrant. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/elacestrant
- AMA 11th
Elacestrant. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/elacestrant
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.